Biobehavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-life Database Analysis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To document glycemic and user-initiated bolus changes following transition from predictive low glucose suspend (PLGS) system to automated insulin delivery (AID) system during real-life use. RESEARCH DESIGN AND METHODS: We conducted analysis of 2,329,166 days (6,381 patient-years) of continuous glucose monitoring (CGM) and insulin therapy data for 19,354 individuals with type 1 Diabetes, during 1-month PLGS use (Basal-IQ technology) followed by 3-month AID use (Control-IQ technology). Baseline characteristics are as follows: 55.4% female, age (median/quartiles/range) 39/19–58/1–92 years, mean ± SD glucose management indicator (GMI) 7.5 ± 0.8. Primary outcome was time in target range (TIR) (70–180 mg/dL). Secondary outcomes included CGM-based glycemic control metrics and frequency of user-initiated boluses. RESULTS: Compared with PLGS, AID increased TIR on average from 58.4 to 70.5%. GMI and percent time above and below target range improved as well: from 7.5 to 7.1, 39.9 to 28.1%, and 1.66 to 1.46%, respectively; all P values <0.0001. Stratification of outcomes by age and baseline GMI revealed clinically significant differences. Glycemic improvements were most pronounced in those <18 years old (TIR improvement 14.0 percentage points) and those with baseline GMI >8.0 (TIR improvement 13.2 percentage points). User-initiated correction boluses decreased from 2.7 to 1.8 per day, while user-initiated meal boluses remained stable at 3.6 to 3.8 per day. CONCLUSIONS: Observed in real life of >19,000 individuals with type 1 diabetes, transitions from PLGS to AID resulted in improvement of all glycemic parameters, equivalent to improvements observed in randomized clinical trials, and reduced user-initiated boluses. However, glycemic and behavioral changes with AID use may differ greatly across different demographic and clinical groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two publications of real-life data, one reporting 9300 users for a year 136 and the other 21,000 users for four months, 137 confirmed that the system performance in real life is virtually identical to its performance in the pivotal clinical trials.[132][133][134]136,137”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“Similar analyses were conducted for all other secondary CGM-based and insulin delivery–based outcomes, which included the metrics recommended by the International Consensus on Time in Range (25): time <54 and <70 mg/dL, time >180 and >250 mg/dL, coefficient of variation, total daily insulin, and the number of user-ini…”
MethodSelf-citationSix-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citationGlucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684 · cited 3×
“Note that the GMI is a unit-less linear function of average glucose, presented sometimes as a percentage because of its clinical analogy with HbA1c (24).”
BackgroundMethodInfluentialSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“Two AID systems, the Medtronic MiniMed 670G/770G (8) and Tandem Diabetes Care t:slim X2 pump with Control-IQ technology (9,10), have U.”
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004736 · Cited by 455
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Bekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Bergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
Brown, S. A., Forlenza, G. P., Bode, B. W., Pinsker, J. E., Levy, C. J., Criego, A. B., Hansen, D. W., Hirsch, I. B., Carlson, A. L., Bergenstal, R. M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0172 · Cited by 286
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
Self-citationReal-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users
Silva, J. D., Lepore, G., Battelino, T., Arrieta, A., Castañeda, J., Grossman, B., Shin, J., & Cohen, O. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0203 · Cited by 229 · cited 1×
“It is important to understand the factors that contribute to this pattern of early rapid improvement that quickly plateaus characteristic of AID use and whether there is indeed a ceiling effect for TIR for people with type 1 diabetes, as seen in these data and with other AID systems (20,27).”
BackgroundRandomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes
Ware, J., Allen, J. M., Boughton, C. K., Wilinska, M. E., Hartnell, S., Thankamony, A., de Beaufort, C., Schierloh, U., Fröhlich-Reiterer, E., Mader, J. K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111673 · Cited by 222 · cited 1×
“have shown positive glycemic outcomes across ages ranging from 1 year (5) to >65 years (6) and for individuals in a state of suboptimal as well as tight diabetes control (7).”
BackgroundBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
One year clinical experience of the first commercial hybrid closed-loop system
Lal, R. A., Basina, M., Maahs, D. M., Hood, K., Buckingham, B., & Wilson, D. M. (2019) · Diabetes Care · doi:10.2337/dc19-0855 · Cited by 215
Messer, L. H., Berget, C., Vigers, T., Pyle, L., Geno, C., Wadwa, R. P., Driscoll, K. A., & Forlenza, G. P. (2020) · Pediatric Diabetes · doi:10.1111/pedi.12971 · Cited by 161 · cited 1×
“This alone is a finding worth noting because too frequently treatments that perform well in controlled clinical trial settings perform suboptimally in real life for a variety of reasons, including human factors (23).”
BackgroundLum, J. W., Bailey, R. J., Barnes-Lomen, V., Naranjo, D., Hood, K. K., Lal, R. A., Arbiter, B., Brown, A. S., DeSalvo, D. J., Pettus, J., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0535 · Cited by 150 · cited 1×
“Several other systems are at various stages in their development, Diabeloop (14), Tidepool Loop (15), the bihormonal artificial pancreas (insulin plus glucagon) from Inreda Diabetic (16), and iLet, in two configurations, insulin only and insulin plus glucagon (17).”
BackgroundBerget, C., Messer, L. H., Vigers, T., Frohnert, B. I., Pyle, L., Wadwa, R. P., Driscoll, K. A., & Forlenza, G. P. (2020) · Pediatric Diabetes · doi:10.1111/pedi.12962 · Cited by 138
McAuley, S. A., Trawley, S., Vogrin, S., Ward, G. M., Fourlanos, S., Grills, C. A., Lee, M. H., Alipoor, A. M., O’Neal, D. N., O’Regan, N. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1667 · Cited by 117
Ware, J., Boughton, C. K., Allen, J. M., Wilinska, M. E., Tauschmann, M., Denvir, L., Thankamony, A., Campbell, F. M., Wadwa, R. P., Buckingham, B. A., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00020-6 · Cited by 101
Karageorgiou, V., Papaioannou, T., Bellos, I., Alexandraki, K., Tentolouris, N., Stefanadis, C., Chrousos, G. P., & Tousoulis, D. (2018) · Metabolism · doi:10.1016/j.metabol.2018.10.002 · Cited by 95
Blauw, H., Onvlee, A. J., Klaassen, M., van Bon, A. C., & DeVries, J. H. (2021) · Diabetes Care · doi:10.2337/dc20-2106 · Cited by 84 · cited 1×
“Several other systems are at various stages in their development, Diabeloop (14), Tidepool Loop (15), the bihormonal artificial pancreas (insulin plus glucagon) from Inreda Diabetic (16), and iLet, in two configurations, insulin only and insulin plus glucagon (17).”
BackgroundAkturk, H. K., Giordano, D., Champakanath, A., Brackett, S., Garg, S., & Snell‐Bergeon, J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13933 · Cited by 80
Castellanos, L. E., Balliro, C. A., Sherwood, J. S., Jafri, R., Hillard, M. A., Greaux, E., Selagamsetty, R., Zheng, H., El-Khatib, F. H., Damiano, E. R., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1086 · Cited by 74 · cited 1×
“Several other systems are at various stages in their development, Diabeloop (14), Tidepool Loop (15), the bihormonal artificial pancreas (insulin plus glucagon) from Inreda Diabetic (16), and iLet, in two configurations, insulin only and insulin plus glucagon (17).”
BackgroundReal‐world performance of the MiniMed™ 670G system in Europe
Da Silva, J., Bosi, E., Jendle, J., Arrieta, A., Castaneda, J., Grossman, B., Cordero, T. L., Shin, J., & Cohen, O. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14424 · Cited by 60 · cited 1×
“It is important to understand the factors that contribute to this pattern of early rapid improvement that quickly plateaus characteristic of AID use and whether there is indeed a ceiling effect for TIR for people with type 1 diabetes, as seen in these data and with other AID systems (20,27).”
BackgroundCandidate Selection for Hybrid Closed Loop Systems
Forlenza, G. P., Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0217 · Cited by 25 · cited 1×
“This finding, with a large group of >4,000 individuals with suboptimal control at baseline, is particularly important and confirms a previous recommendation that AID systems be considered for those with poorly managed diabetes (26).”
ResultSelf-citationDecision Support Systems and Closed Loop
Nimri, R., Ochs, A. R., Pinsker, J. E., Phillip, M., & Dassau, E. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.2504 · Cited by 13
Decision Support Systems and Closed-Loop
Nimri, R., Kovatchev, B. P., & Phillip, M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.2505 · Cited by 7
Self-citation
Cited by
Beck, R. W., Kanapka, L. G., Breton, M. D., Brown, S. A., Wadwa, R. P., Buckingham, B. A., Kollman, C., & Kovatchev, B. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0558 · Cited by 111
“These findings are consistent with the real-world data reported by Kovatchev et al. 13 Despite performing fewer user-initiated boluses, participants with high baseline HbA1c levels showed the largest improvement in HbA1c compared with the Control group; in participants with baseline HbA1c ‡ 8.5%,…”
InfluentialSelf-citationForlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
Real-world evidence of automated insulin delivery system use
Considine, E. G., & Sherr, J. L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0442 · Cited by 59
“39,40 The majority of AID system studies included < 100 users, 39,41–51 yet 6 articles encompassed data from > 3000 users 40,52–56 and 3 reports had > 10,000 users.”
InfluentialRenard, E., Joubert, M., Villard, O., Dreves, B., Reznik, Y., Farret, A., Place, J., Breton, M. D., Kovatchev, B. P., & iDCL Trial Research Group (2023) · Diabetes Care · doi:10.2337/dc23-0685 · Cited by 51
Self-citationKovatchev, B. P., Colmegna, P. H., Pavan, J., C., J. L. D., Villa-Tamayo, M. F., Koravi, C. L. K., Santini, G., Alix, C., Stumpf, M. M., & Brown, S. A. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01679-y · Cited by 64
“Nevertheless, it is evident that, with the expected low incidence of hypoglycaemia in this population 1,13 , ABC effectively and safely reduced exposure to hyperglycaemia.”
InfluentialSelf-citation
Metadata
- Authors
- Kovatchev, B. P., Singh, H., Mueller, L., & Gonder-Frederick, L. A.
- Affiliations
- University of Virginia (US)
- Tandem Diabetes Care (United States) (US)
- 2Tandem Diabetes Care, San Diego, CA
- Corresponding author
- Kovatchev, Boris P.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-20
- Volume
- 45
- Issue
- 11
- Pages
- 2636-2643
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC9862393
- OpenAlex
- W4297874927
- Semantic Scholar
- 19eea3683df3e9d8cbaea7cbb17831fef0f35987
- Cited by
- 49
- References
- 28
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 15 · 2023: 8
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Virginia (Strategic Investment Fund Project #88)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- artificial pancreas, type 1 diabetes, predictive low glucose suspend, Control-IQ, continuous glucose monitoring, glycemic control, time in range, age differences, glucose management indicator
- MeSH terms
- Adolescent, Blood Glucose, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemic Agents, Insulin, Male, Blood Glucose Self-Monitoring, Insulin, Regular, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.